PNRR POC - TRUST Engineered lisyl oxidase lipid-based nanovesicles for the treatment of solid tumors: on the path to clinical application

TRUST focus on the improvement of the standard chemotherapy strategies for localized and metastatic treatment of triple negative breast cancer (TNBC) and sarcomas through an innovative approach based on nanoplatforms.  IRST developed and patented a lipid-based vesicle functionalized with a LOX antibody (LIPOLOX) loaded with standard chemotherapy (PCT 144891 - international application no. PCT/EP2020/077465) for the treatment of TNBC. LIPO-LOX is an alternative delivery approach that revealed significant advantages in terms of increased therapeutic efficacy and reduced systemic toxicity.

TRUST aims to the improvement and validation of LIPO-LOX delivery system for the treatment of TNBC. To reach this aim, the project involves the combination of different 3D in vitro models, the use of biological material and in vivo models to test in an integrated manner LIPO-LOX mechanism of action, efficacy, and safety. TRUST, beside confirming its efficacy on TNBC, will collect and provide the first data on sarcomas, that represent a rare cancers and orphans of effective treatments.The expected results will pave the way to design personalized therapeutic strategies and to plan tailored clinical trials for this innovative therapeutic treatment.